Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Pharma to Promote Elcitonin for Pain in Osteoporosis
April 5, 2004
- BULLETIN
April 5, 2004
- Midterm Management Plan for Mediceo Group Announced
April 5, 2004
- PRESS SEMINAR
April 5, 2004
- Contract Mfg Now Accounts for Half of Sales: Nipro Pharma
April 5, 2004
- JMA Announces Report on Medical Practices, Bioethics
April 5, 2004
- Drug Organization Investment Project Receives Qualified Praise from Participants: JPMA Survey
April 5, 2004
- OTC NEWS IN BRIEF
April 5, 2004
- BUSINESS NEWS IN BRIEF
April 5, 2004
- Iryo Proverbs Reveal Japanese Spirit (18)
April 5, 2004
- Janssen Pharmaceutical Aims at Sales of \100 Bil. in 2006: Mr Sekiguchi
April 5, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 5, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
April 5, 2004
- Kyowa Hakko to License "Potelligent" Technology to US Companies
April 5, 2004
- Somusho Asks Korosho to Simplify Approval Modification Procedure
April 5, 2004
- BULLETIN
April 5, 2004
- Off-label Use of Drugs in Children Reported: Korosho Panel
April 5, 2004
- REGULATORY NEWS IN BRIEF
April 5, 2004
- Generics' Share Up to 6.3% on Purchase Price Basis at National Hospitals
April 5, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 5, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…